CanSino Claims Lead In COVID-19 Vaccine Race And Takes Swipe At Moderna’s Ethics

Will Be First To Publish Phase II Results

Vaccines veteran calls Moderna ‘shabby’ for lack of transparency and shares sell-off, and flags CanSino’s own forthcoming Phase II results.

A scientist in a medical laboratory with a dispenser in his hands is doing an analysis.2019-nCoV; coronavirus; China;
One of several frontrunners, CanSino is gearing up to start make-or-break Phase III trials

Chinese company CanSino Biologics is to shortly publish full Phase II results from its COVID-19 vaccine candidate - which it says makes it a leader both in development times and research transparency in the race to develop a vaccine against the coronavirus.

Speaking to Scrip, Pierre Morgon, the company’s senior vice president of international business said the results would be published in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip